Home/Pipeline/Flutiform

Flutiform

Asthma

MarketedActive

Key Facts

Indication

Asthma

Phase

Marketed

Status

Active

Company

KYORIN Pharmaceutical

About KYORIN Pharmaceutical

KYORIN Pharmaceutical is a publicly listed Japanese pharmaceutical leader with a mission to contribute to people's health by addressing unmet medical needs. Founded in 1923 and publicly listed in 1999, the company has achieved significant scale with a market valuation of ~$94.8B, built on a foundation of established products in respiratory and urology. Its current strategy, outlined in the 'Vision 110' long-term plan, focuses on transforming its business structure to become a core innovator in new pharmaceuticals while expanding its healthcare portfolio.

View full company profile

Therapeutic Areas

Respiratory Urology Otolaryngology Infectious Disease Pain

Other Asthma Drugs

Drug	Company	Phase	Status
Technegas® for Asthma	Cyclomedica	Phase 2	Active
Asthma Candidate	Teva	Phase 3	Active
Montelukast Amorphous Form	Morepen Laboratories	Phase-2	Active
Chitinase Inhibitor	Lead Discovery Siena	Discovery	Active
RIG-101	RIGImmune	Pre-clinical	Active
SKB378	Klus Pharma	Phase 1	Active
Asthma Clinical Trials	American Health Research	Not Disclosed	Active
Advanced Asthma Products	Polpharma	Not Disclosed	Active
Solrikitug	Uniquity Bio	Phase 2	Active
Asthma Trial	Science 37	Phase 3	Completed/Highlighted
CAL-4	Calyxha Biotechnologies	Preclinical	Active
Digital Biomarker for Asthma	electronRx	Early Development	Active